Michael John Tomsicek's Equity Transaction

Michael John Tomsicek, a director at Acrivon Therapeutics, Inc., acquired 9,366 shares of Common Stock on May 18, 2026. This acquisition was made through restricted stock units (RSUs) which vest in full on May 18, 2027, contingent upon continued service. The transaction code was "A" for acquisition, with a reported price of $0.00 per share. Following this transaction, Tomsicek holds a total of 9,366 shares. The filing was made on Form 4, and the signature date was May 20, 2026.